Sight Sciences

In 2011, founders Paul and Dr. David Badawi recognized a critical gap in eyecare: traditional surgical approaches to treating glaucoma and dry eye disease were often invasive, required implants, and demanded compromises from patients in terms of recovery time and risk. Driven by a shared passion for improving patient outcomes through minimally invasive technologies, the brothers established Sight Sciences to develop interventional solutions that could transform how eyecare providers treat some of the world's most prevalent eye diseases.

Sight Sciences has since grown into a publicly traded medical technology company (Nasdaq: SGHT) focused on developing and commercializing innovative surgical systems for glaucoma management and dry eye disease treatment. The company's flagship products include the OMNI Surgical System and OMNI Edge Surgical System for minimally invasive glaucoma surgery (MIGS), the SION Surgical System for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye disease caused by meibomian gland dysfunction. Headquartered in Menlo Park, California with operations in Texas, Sight Sciences continues to pursue its mission of providing eyecare providers with transformative, clinically-proven technologies that are intuitive, less invasive, and more intelligent than conventional treatment approaches.